Amundi Reduces Holdings in BioNTech SE (NASDAQ:BNTX)

Amundi decreased its holdings in BioNTech SE (NASDAQ:BNTX) by 23.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 281,013 shares of the company’s stock after selling 85,658 shares during the quarter. Amundi’s holdings in BioNTech were worth $34,326,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its holdings in BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after purchasing an additional 150 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in BioNTech by 3.9% during the fourth quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock valued at $666,000 after purchasing an additional 224 shares in the last quarter. Atomi Financial Group Inc. lifted its holdings in BioNTech by 6.7% during the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company’s stock valued at $414,000 after purchasing an additional 229 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BNTX. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective on the stock. BMO Capital Markets lifted their price objective on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.65.

BioNTech Stock Up 2.0 %

Shares of BNTX opened at $100.31 on Thursday. The firm has a market capitalization of $24.05 billion, a P/E ratio of -47.77 and a beta of 0.30. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average price of $116.18 and a 200-day moving average price of $113.04.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same period in the prior year, the firm earned $1.90 earnings per share. The firm’s revenue for the quarter was down 19.5% compared to the same quarter last year. Equities research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.